PAR General discussion, page-256

The AGM will be absolutely crucial IMO. We are all in for the long term multi-bagger, but the market is saying there won't be a long term if PR and Skeritt can't give us clear answers and begin delivering on promises. There are only about 300k shares in the buy queue all the way down to $1.25. That is very unhealthy. If the SP tanks to that level and then PAR has a cap raise, it will be very ugly. HC posters have asked a lot of great questions, e.g. where is the long overdue P2 review? Lack of a meaningful progress report on the 008 trial is a worry. What is happening there? How much $ is actually budgeted just for the dosing trial which the FDA now requires before the main P3 can even begin? And what $ will be required to complete P3 which now looks like finishing in 2026 at best. Appointment of a new CEO is extremely urgent! Is the board even interviewing a short list yet? Since the IND announcement, the SP has gone from $2.30 to $1.70. What newsflow between now and 2026 will bring back buyers and maybe sting a few shorters? Arguably a deal with pharma may be about the only salvation unless there is a rabbit in the hat that we don't know about. PR has been talking about a deal with pharma for at least 4 years, but nada. There are some good intermediary companies that specialise in brokering deals between biotechs and pharma. Some of them know pharma BD on a 1st name basis. Surely there is no justification for the AGM resolution that would give PR 450,000 more shares on top of his rem which is apparently over $1 million pa.